12:00 AM
 | 
Dec 10, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Horizon Pharma sales and marketing update

Horizon Pharma launched Rayos prednisone delayed-release tablets in the U.S., with an initial focus on treating rheumatic disease including rheumatoid arthritis and polymyalgia rheumatica. The wholesale acquisition cost (WAC) is $7 per day for a once-daily 5 mg tablet. FDA approved the delayed-release oral formulation of low-dose prednisone in...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >